Each gram of gel contains Clindamycin phosphate equivalent to Clindamycin 10 mg.
Pharmacology: Although Clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active Clindamycin. Clindamycin in vitro active to Propionibacterium acnes. Free fatty acids on the skin surface has been decreased from approximately 14% to 2% following application of Clindamycin.
For treatment of acne vulgaris.
Apply lightly to the affected skin area twice daily.
No special medications. If allergic reactions occur, the usual agents (corticosteroids, adrenalin, and antihistamine) should be available for emergency treatment.
Patients who have hypersensitivity to Clindamycin.
Patients who have a history of regional enteritis or ulcerative colitis.
Patients who have a history of antibiotic - associated colitis.
Use of the topical formulation of Clindamycin results in absorption of the antibiotic from the skin surface, so that like administered orally when significant diarrhea occurs, the drug should be discontinued.
Used with caution in patients with atopic individuals.
Used with caution in pregnant and nursing women, this drug should be used only if clearly needed.
Safety and efficacy in pediatric patients under the age of 12 has not been established.
Burning, itching, skin dryness, erythema, oily skin, peeling, skin irritation, gram - negative folliculitis abdominal pain, and gastrointestinal disturbances.
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents, therefore it should be used with caution in patients receiving such agents. In vitro antagonism has been demonstrated between Clindamycin and Erythromycin. It is advised to separate the time of administration of each drug, because it is possible to be clinically significant effect.
D10AF01 - clindamycin ; Belongs to the class of topical antiinfective preparations used in the treatment of acne.
Topical gel (tube) 1% x 10 g x 1's.